A Phase 1 Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Moderate or Severe Systemic Lupus Erythematosus
Latest Information Update: 19 Jun 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; ET 901 (Primary) ; Fludarabine (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- Sponsors EdiGene Inc
Most Recent Events
- 19 Jun 2024 Last checked against:ClinicalTrials.gov: US National Institutes of Health
- 14 Jun 2024 Status changed to not yet recruiting.
- 14 Jun 2024 Planned initiation date changed from 15 Apr 2024 to 24 Jul 2024.